<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Relay Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/relay-therapeutics-inc</link>
<description>Latest news and press releases for Relay Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/relay-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b89c78dffbe2df1150eb.webp</url>
<title>Relay Therapeutics Inc</title>
<link>https://6ix.com/company/relay-therapeutics-inc</link>
</image>
<item>
<title>Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-announce-first-quarter-2026-financial-results-and-corporate-highlights-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-announce-first-quarter-2026-financial-results-and-corporate-highlights-on-may-5-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report first quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Tuesday, May 5, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision med</description>
</item>
<item>
<title>Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline-metastatic-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-clinical-data-for-zovegalisib-plus-atirmociclib-triplet-combination-supportive-of-further-development-in-frontline-metastatic-breast-cancer</guid>
<pubDate>Mon, 27 Apr 2026 10:00:00 GMT</pubDate>
<description>Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line); ORR is similar across kinase and non-kinase PIK3CA mutations Phase 3 frontline trial in endocrine sensitive patients expected to initiate in early 2027, subject to regulatory feedback Supply agreement in place with Pfizer to supply atirmociclib</description>
</item>
<item>
<title>Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-in-vascular-anomalies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-present-initial-clinical-data-on-zovegalisib-in-vascular-anomalies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026</guid>
<pubDate>Thu, 02 Apr 2026 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that initial clinical results and preclinical data for zovegalisib (RLY-2608) in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026, taking place May 1</description>
</item>
<item>
<title>Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-data-from-zovegalisib-fulvestrant-at-the-phase-3-dose-of-400mg-bid-fed-at-esmo-targeted-anticancer-therapies-congress-2026</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-data-from-zovegalisib-fulvestrant-at-the-phase-3-dose-of-400mg-bid-fed-at-esmo-targeted-anticancer-therapies-congress-2026</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with</description>
</item>
<item>
<title>Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-outlines-anticipated-2026-milestones</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-outlines-anticipated-2026-milestones</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced in 2026 Initial Phase 1/2 data of zovegalisib + fulvestrant at 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO TAT on March 16, 2026 Approximately $555 million in cash, cash equivalents and investments at end of Q4 2025 CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWI</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-march</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-participate-in-two-upcoming-investor-conferences-in-march</guid>
<pubDate>Mon, 23 Feb 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in March: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 3:10 p.m. ETBarclays 28th Annual Global Healthcare Conference on Wednesday, March 11,</description>
</item>
<item>
<title>Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-corporate-highlights-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 22:55:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small m</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-guggenheim-emerging-210500322</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-guggenheim-emerging-210500322</guid>
<pubDate>Wed, 04 Feb 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay</description>
</item>
<item>
<title>Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-zovegalisib-granted-breakthrough-therapy-designation-us</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-zovegalisib-granted-breakthrough-therapy-designation-us</guid>
<pubDate>Tue, 03 Feb 2026 05:00:00 GMT</pubDate>
<description>Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with</description>
</item>
<item>
<title>Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-efficacy-subset-analysis-zovegalisib-rly-2608</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-efficacy-subset-analysis-zovegalisib-rly-2608</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset</description>
</item>
<item>
<title>Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable,</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-november-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-november-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company</description>
</item>
<item>
<title>Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announce-third-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announce-third-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-september-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-september-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company</description>
</item>
<item>
<title>Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-second-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-reports-second-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2-</description>
</item>
<item>
<title>Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announce-second-quarter-2025-financial-results-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announce-second-quarter-2025-financial-results-and-corporate</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug</description>
</item>
<item>
<title>Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-appoints-claire-mazumdar-phd-board-directors-2025-06-11</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-appoints-claire-mazumdar-phd-board-directors-2025-06-11</guid>
<pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug</description>
</item>
<item>
<title>Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-updated-data-rly-2608-fulvestrant-further-demonstrating</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-announces-updated-data-rly-2608-fulvestrant-further-demonstrating</guid>
<pubDate>Mon, 02 Jun 2025 04:00:00 GMT</pubDate>
<description>Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2-</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-june-2025-05-29</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-june-2025-05-29</guid>
<pubDate>Thu, 29 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug</description>
</item>
<item>
<title>Relay Therapeutics to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-2025-05-08</link>
<guid isPermaLink="true">https://6ix.com/company/relay-therapeutics-inc/news/relay-therapeutics-participate-two-upcoming-investor-conferences-2025-05-08</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug</description>
</item>
</channel>
</rss>